Clinical Report: Neoadjuvant Chemotherapy Strategies and a Decade of Survival Outcomes in Advanced Ovarian Cancer
Overview
This study evaluates the long-term survival outcomes associated with neoadjuvant chemotherapy (NACT) in advanced ovarian cancer. It finds no significant association between NACT adoption and 10-year survival rates.
Background
The management of advanced-stage epithelial ovarian cancer typically involves a combination of cytoreductive surgery and chemotherapy. The sequence of these treatments, particularly the role of NACT versus primary debulking surgery, remains a subject of debate among clinicians, impacting treatment decisions and patient outcomes.
Data Highlights
Program Type
10-Year Survival Probability
10-Year Restricted Mean Survival Time (months)
Low-Use Programs
15.1% to 19.1%
45.7 to 51.4
High-Use Programs
15.6% to 20.0%
47.1 to 53.5
Key Findings
NACT use increased from 21.5% to 42.8% in high-use programs.
10-year survival probability improved similarly in both low-use and high-use programs.
No significant association was found between NACT adoption and long-term survival outcomes.
Standardized 10-year survival probability increased by 4.0 percentage points in low-use and 4.3 percentage points in high-use programs.
10-year restricted mean survival time rose in both program types, indicating comparable improvements.
Clinical Implications
The findings indicate that NACT does not appear to confer a long-term survival advantage over traditional treatment approaches.
Conclusion
The study highlights the need for ongoing evaluation of treatment strategies in advanced ovarian cancer regarding the long-term impact of NACT on survival outcomes.
by Alex E. R. Powers, Gretchen Davis, Deshae Jenkins, Alicia Youssef, William Manning, Jason D. Wright, Nancy L. Keating, Amy Bregar, Alejandro Rauh-Hain, Alexander Melamed